PT  - JOURNAL ARTICLE
AU  - Kalika Dubey
AU  - Charu Sharma
AU  - Suma Shet
AU  - Shashank Shekhar
TI  - Successful outcome in a compound heterozygote haemoglobin E/beta-thalassaemia in pregnancy
AID  - 10.1136/bcr-2022-252829
DP  - 2023 Feb 01
TA  - BMJ Case Reports
PG  - e252829
VI  - 16
IP  - 2
4099  - http://casereports.bmj.com/content/16/2/e252829.short
4100  - http://casereports.bmj.com/content/16/2/e252829.full
SO  - BMJ Case Reports2023 Feb 01; 16
AB  - Haemoglobin E (HbE) affects at least 1 million people around the world. The carrier frequency of HbE/beta-thalassaemia (HbE/β-thalassaemia) is highest in Southeast Asia. In India, the highest frequency is observed in the northeast region. Distinguishing between homozygous HbE disease and HbE/β-thalassaemia is a challenge to the haematopathologist as well as to the treating obstetrician because both are clinically and haematologically similar, posing a difficulty in managing anaemia and assessing the fetal risk for the same disease. This article reports a case of compound heterozygote HbE/β-thalassaemia in pregnancy and its successful outcome.